Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients
Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of patients…